MelissaLeighLarsonMD

PubMed

• COVID-19 thromboembolism incidence, risk factors, and anticoagulation practices from a Chicago metropolitan US population.
  Stephanie Berg, Seo-Hyun Kim, Amy Wozniak, Oluwatobi Odetola, Saad Arain, Ahmed Aleem, James Coggan, Ami Dave, Elizabeth Elliott, Ryan Guerrettaz, Hina Dalal, Raymond ...> ;American Journal of Hematology. 2022 Jun 1
• 31 citations
  Structural racism is a mediator of disparities in acute myeloid leukemia outcomes.
  Abraham, I., Rauscher, G., Patel, A., Pearse, W., Rajakumar, P., Burkart, M., Aleem, A., Dave, A., Bharadwaj, S., Paydary, K., Acevedo-Mendez, M., Goparaju, K., Gomez,...> ;Blood. 2022 Apr 7
• 4 citations
  Pembrolizumab-induced autoimmune haemolytic anemia in a patient with chronic lymphocytic leukaemia successfully treated with ibrutinib.
  Nicole K. Yun, Taha Alrifai, Ira Miller, Melissa L. Larson> ;BMJ Case Reports. 2021 Sep 21
• 21 citations
  Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)
  Se young Han, Krzysztof Mrózek, Jenna M. Voutsinas, Qian Wu, Elizabeth A. Morgan, Hanne Vestergaard, Robert S. Ohgami, Philip M. Kluin, Thomas Kielsgaard Kristensen, S...> ;Blood Advances. 2021 May 25
• 6 citations
  Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia
  Gail J. Roboz, Melissa L. Larson, S. Eric Rubenstein, Scott R. Solomon, Gary J. Schiller, Qi An, Michael Chiarella, Arthur C. Louie, Tara L. Lin> ;Leukemia & Lymphoma. 2020 Feb 26
• 9 citations
  Erythroid differentiation of myeloblast induced by gilteritinib in relapsed FLT3-ITD-positive acute myeloid leukemia.
  Hyun Don Yun, Sunita Nathan, Melissa C. Larson, Mohammad Junaid Hussain, Deborah A. Katz, Ankur Varma, Ira Miller, Celalettin Ustun> ;Blood Advances. 2019 Nov 26
• The relationship between ehrlichiosis and the development of hematologic malignancies.
  Candice Schwartz, Deborah A. Katz, Melissa L. Larson, Nancy Licciardi, Charles A. Kallick, Timothy M. Kuzel> ;Medical Hypotheses. 2018 Dec 1
• 6 citations
  Phase 2 study of CHOP‑R‑14 followed by 90Y‑ibritumomab tiuxetan in patients with previously untreated diffuse large B‑cell lymphoma
  Reem Karmali, Melissa L. Larson, Jamile M. Shammo, Stephanie A. Gregory, Teresa O'Brien, Parameswaran Venugopal> ;Molecular and Clinical Oncology. 2017 Apr 1
• 8 citations
  Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemia.
  Reem Karmali, Melissa L. Larson, Jamile M. Shammo, Sanjib Basu, Kent W. Christopherson, Jeffrey A. Borgia, Parameswaran Venugopal> ;Leukemia & Lymphoma. 2015 Mar 4
• 118 citations
  Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
  Jorge E. Cortes, Stuart L. Goldberg, Eric J. Feldman, David A. Rizzeri, Donna E. Hogge, Melissa L. Larson, Arnaud Pigneux, Christian Recher, Gary J. Schiller, Krzyszto...> ;Cancer. 2015 Jan 15
• 10 citations
  Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients.
  Reem Karmali, Laura A. Paganessi, Robin R. Frank, Sucheta Jagan, Melissa L. Larson, Parameswaran Venugopal, Stephanie A. Gregory, Kent W. Christopherson> ;Journal of Leukocyte Biology. 2013 Jan 1
• 3 citations
  Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine
  Sucheta Jagan, Laura A. Paganessi, Robin R. Frank, Parameswaran Venugopal, Melissa L. Larson, Kent W. Christopherson> ;Advances in Hematology. 2012 Sep 23
• 9 citations
  Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy...
  Reem Karmali, Melissa L. Larson, James E. Wooldridge, Stephanie A. Gregory, Teresa O'Brien, Jamile M. Shammo, Katherine Bueschel, Parameswaran Venugopal> ;Leukemia & Lymphoma. 2011 Oct 24
• Etoposide and cytarabine as an effective and safe cytoreductive regimen for relapsed or refractory acute myeloid leukemia.
  Nair G, Karmali R, Gregory SA, Shammo JM, Fung HC, Jimenez A, Venugopal P, Larson ML> ;J. Clin. Oncol.. 2011-05-20
• 2 citations
  Clofarabine: a new treatment option for patients with acute myeloid leukemia.
  Melissa L. Larson, Parameswaran Venugopal> ;Expert Opinion on Pharmacotherapy. 2009 May 23
• 2 citations
  Posttransplant lymphoproliferative disorder: extranodal marginal zone lymphoma occurring after renal transplantation.
  Justin M Goldfarb, Melissa L. Larson, Parameswaran Venugopal, Stephanie A. Gregory> ;Clinical Advances in Hematology & Oncology. 2006 Aug 1
• HIV-related lymphoma treated with maintenance thalidomide.
  Melissa L. Larson, Sari H. Enschede, Stephanie A. Gregory> ;Clinical Advances in Hematology & Oncology. 2005 Mar 1
• Join now to see all

Abstracts/Posters

• Role of Racial, Demographic and Socioeconomic Disparities in Treatment Patterns and Outcomes in AML
  Melissa L. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

• Final Safety and Efficacy Results from the CPX-351 Early Access Program (EAP) for Older Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Timed sequential therapy with high-dose cytarabine and mitoxantrone as an effective and safe induction regimen for acute myeloid leukemia. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018